Clinical trials · Tennessee
Metastatic Cancer clinical trials in Tennessee
We’re tracking 193 recruiting metastatic cancer studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT05653388Recruiting
Study biomarker testing in metastatic leiomyosarcoma
This trial looks at lab markers (biomarkers) in tumor samples from people with leiomyosarcoma that has spread or can’t be fully removed. It also enrolls people who are receiving certain first-line chemotherapy, and your results may help guide future treatment decisions.
Nashville, TennesseeAges Any age - NCT06567015RecruitingPhase 1/Phase 2
STX-241 for advanced EGFR-mutant lung cancer after TKI failure
This trial tests an experimental drug called STX-241 for people with a specific type of advanced lung cancer (NSCLC) that has an EGFR mutation (exon 19 deletion or L858R) and has stopped responding to a third-generation EGFR inhibitor (like osimertinib). The drug aims to target a new mutation, C797X, that sometimes appears after osimertinib stops working.
Nashville, TennesseeAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Knoxville, TennesseeAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Nashville, TennesseeAges 18 years+ - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Nashville, TennesseeAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Nashville, TennesseeAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Collierville, TennesseeAges Any age - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Chattanooga, TennesseeAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Alcoa, TennesseeAges 18 years+ - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
Nashville, TennesseeAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Nashville, TennesseeAges 18 years+ - NCT07291037RecruitingPhase 3
Study of datopotamab deruxtecan vs docetaxel for advanced lung cancer
This trial tests a new drug, datopotamab deruxtecan, against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatment. It is for those who do not have certain genetic changes (like EGFR, ALK, or ROS1) and whose tumors have a protein called TROP2.
Memphis, TennesseeAges 18 years+ - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Nashville, TennesseeAges 18 years+ - NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT07194044RecruitingPhase 1
Testing a treatment schedule for metastatic Ewing sarcoma
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
Nashville, TennesseeAges 1 year+ - NCT07217028RecruitingPhase 1
Safety study of a new PET tracer for head and neck cancer
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
Nashville, TennesseeAges 18 years+ - NCT04142437Recruiting
Tracking how larotrectinib works for NTRK fusion cancers in routine care
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Memphis, TennesseeAges Any age - NCT05691478RecruitingPhase 2/Phase 3
Cabozantinib added to chemotherapy for new osteosarcoma
This trial tests whether adding cabozantinib to standard chemotherapy works better in children and young adults with newly diagnosed high-grade osteosarcoma. It may help by improving control of the cancer, especially for higher-risk cases.
Knoxville, TennesseeAges Up to 40 years - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Knoxville, TennesseeAges 2–21 - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Nashville, TennesseeAges 18 years+ - NCT05040360RecruitingPhase 2
Chemotherapy after surgery for high-risk pancreatic NET tumors
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Collierville, TennesseeAges 18 years+ - NCT06016855RecruitingPhase 4
Surgery before radiation therapy for neuroendocrine tumors
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
Nashville, TennesseeAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Nashville, TennesseeAges 18 years+
Metastatic Cancer trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting metastatic cancer studies listed above.
- Vanderbilt University Medical Center · 14 studies
- SCRI Oncology Partners · 4 studies
- St. Jude Children's Research Hospital · 3 studies
- Baptist Memorial Hospital and Cancer Center-Collierville · 2 studies
- Baptist Memorial Hospital and Cancer Center-Memphis · 2 studies
- East Tennessee Children's Hospital · 2 studies
- Research Site · 2 studies
- University Cancer Specialists - Alcoa · 2 studies
What taking part in a metastatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Cancer trials in other states
Common questions
- Are there metastatic cancer clinical trials in Tennessee?
- Yes. We're currently tracking 193 recruiting metastatic cancer studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic cancer study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic cancer studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.